SI3587418T1 - Zaviralci creb vezavnega proteina (cbp) - Google Patents

Zaviralci creb vezavnega proteina (cbp)

Info

Publication number
SI3587418T1
SI3587418T1 SI201930136T SI201930136T SI3587418T1 SI 3587418 T1 SI3587418 T1 SI 3587418T1 SI 201930136 T SI201930136 T SI 201930136T SI 201930136 T SI201930136 T SI 201930136T SI 3587418 T1 SI3587418 T1 SI 3587418T1
Authority
SI
Slovenia
Prior art keywords
cbp
binding protein
protein inhibitors
creb binding
creb
Prior art date
Application number
SI201930136T
Other languages
English (en)
Slovenian (sl)
Inventor
Shawn E. R. Schiller
Torsten Herbertz
Hongbin Li
Bradford Graves
Steven Mischke
Angela V. WEST
Anna Ericsson
Jennifer R. DOWNING
Original Assignee
Forma Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/051235 external-priority patent/WO2019055877A1/en
Application filed by Forma Therapeutics, Inc. filed Critical Forma Therapeutics, Inc.
Priority claimed from EP19183741.8A external-priority patent/EP3587418B1/en
Publication of SI3587418T1 publication Critical patent/SI3587418T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201930136T 2018-06-29 2019-07-01 Zaviralci creb vezavnega proteina (cbp) SI3587418T1 (sl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862692593P 2018-06-29 2018-06-29
PCT/US2018/051235 WO2019055877A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
PCT/US2018/051214 WO2019055869A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
US201962819490P 2019-03-15 2019-03-15
PCT/US2019/039936 WO2020006483A1 (en) 2018-06-29 2019-06-28 Inhibiting creb binding protein (cbp)
US16/457,596 US10870648B2 (en) 2018-06-29 2019-06-28 Inhibiting CREB binding protein (CBP)
EP19183741.8A EP3587418B1 (en) 2018-06-29 2019-07-01 Inhibitors of creb binding protein (cbp)

Publications (1)

Publication Number Publication Date
SI3587418T1 true SI3587418T1 (sl) 2022-03-31

Family

ID=68987627

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201930136T SI3587418T1 (sl) 2018-06-29 2019-07-01 Zaviralci creb vezavnega proteina (cbp)

Country Status (26)

Country Link
US (3) US10870648B2 (enExample)
EP (1) EP3998266A1 (enExample)
JP (4) JP6781806B2 (enExample)
KR (2) KR102805503B1 (enExample)
CN (2) CN112513038B (enExample)
AU (3) AU2019295790B2 (enExample)
BR (1) BR112020026783A2 (enExample)
CA (1) CA3105099A1 (enExample)
CY (1) CY1124762T1 (enExample)
DK (1) DK3587418T3 (enExample)
ES (1) ES2900105T3 (enExample)
HR (1) HRP20211698T1 (enExample)
HU (1) HUE056885T2 (enExample)
IL (3) IL321337A (enExample)
LT (1) LT3587418T (enExample)
MA (1) MA50675B1 (enExample)
MX (2) MX2023013508A (enExample)
PL (1) PL3587418T3 (enExample)
PT (1) PT3587418T (enExample)
RS (1) RS62732B1 (enExample)
SA (1) SA520420909B1 (enExample)
SG (1) SG11202012767UA (enExample)
SI (1) SI3587418T1 (enExample)
SM (1) SMT202100636T1 (enExample)
WO (1) WO2020006483A1 (enExample)
ZA (2) ZA202100509B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019295790B2 (en) * 2018-06-29 2023-07-13 Forma Therapeutics, Inc. Inhibiting creb binding protein (CBP)
EP3937940A4 (en) 2019-03-15 2022-12-21 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
CN113784967B (zh) * 2019-03-15 2024-07-26 福马治疗股份有限公司 用于治疗雄激素受体阳性形式的癌症的组合物和方法
CA3183982A1 (en) 2020-06-25 2021-12-30 Stefanie Fluckiger-Mangual A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc
IL299344A (en) 2020-06-25 2023-02-01 Tolremo Therapeutics Ag Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) * 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404207A (en) 1981-11-06 1983-09-13 Riker Laboratories, Inc. Antimicrobial 8-substituted benzo [IJ]quinolizines
US5138089A (en) * 1986-06-27 1992-08-11 The Procter & Gamble Company Chromophores, sunscreen compositions and methods for preventing sunburn
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
KR100865775B1 (ko) 2000-11-20 2008-10-29 메르크 파텐트 게엠베하 키랄 광이성질성 화합물
WO2003033517A1 (en) 2001-10-17 2003-04-24 The University Of British Columbia Ship 1 modulators
WO2003045929A1 (en) 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Bicyclic derivative, process for producing the same, and use
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
IN2003CH00929A (enExample) 2003-11-13 2008-10-06
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
WO2005099688A2 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
JP2009520038A (ja) 2005-12-19 2009-05-21 ジェネンテック・インコーポレーテッド ピリミジンキナーゼインヒビター
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
WO2007133653A2 (en) 2006-05-09 2007-11-22 Hemaquest Pharmaceuticals, Inc. Methods for treating blood disorders
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
CA2574531C (en) 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
WO2008157680A2 (en) 2007-06-21 2008-12-24 The Wistar Institute Methods and compositions for modulating p300/cbp activity
CN101687815A (zh) 2007-06-26 2010-03-31 塞诺菲-安万特股份有限公司 苯并咪唑和氮杂苯并咪唑的区域选择性铜催化合成
JP5223864B2 (ja) 2007-06-27 2013-06-26 大正製薬株式会社 11β−HSD1阻害活性を有する化合物
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
HUE034598T2 (en) 2008-06-16 2018-02-28 Univ Tennessee Res Found Compound for cancer treatment
US8604030B2 (en) * 2009-03-27 2013-12-10 Kowa Company, Ltd. Fused piperidine compound and pharmaceutical containing same
US20100305093A1 (en) 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
CA2758904C (en) 2009-04-15 2017-04-04 Jw Pharmaceutical Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
ES2425091T3 (es) 2009-05-26 2013-10-11 Exelixis, Inc. Benzoxazepinas como inhibidores de PI3K/mTOR y sus métodos de uso y fabricación
WO2010138490A1 (en) 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and methods of their use and manufacture
WO2011085039A2 (en) 2010-01-05 2011-07-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
WO2011109059A1 (en) 2010-03-01 2011-09-09 Gtx, Inc. Compounds for treatment of cancer
CN103038229B (zh) * 2010-05-26 2016-05-11 桑诺维恩药品公司 杂芳基化合物及其使用方法
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
CA2827392A1 (en) 2011-02-24 2012-08-30 Emory University Noggin blocking compositions for ossification and methods related thereto
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013148114A1 (en) 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use
US9211333B2 (en) 2012-06-05 2015-12-15 Hong Kong Baptist University Anti-cancer agents synthesized based on miliusane compounds
IN2015DN02008A (enExample) 2012-09-21 2015-08-14 Advinus Therapeutics Ltd
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
CA2915622C (en) 2013-06-21 2020-08-18 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
MX365864B (es) 2013-06-21 2019-06-18 Zenith Epigenetics Ltd Inhibidores de bromodominio biciclicos novedosos.
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
DE102013215912B3 (de) 2013-08-12 2015-02-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung
AR098414A1 (es) 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
US9388161B2 (en) 2013-11-18 2016-07-12 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as BET bromodomain inhibitors
CN106029076B (zh) 2013-11-18 2019-06-07 福马疗法公司 作为bet溴域抑制剂的苯并哌嗪组合物
EP3193866A1 (en) 2014-09-19 2017-07-26 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
US9763922B2 (en) 2014-11-27 2017-09-19 Genentech, Inc. Therapeutic compounds and uses thereof
US10435402B2 (en) 2015-01-08 2019-10-08 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
EP3454945B1 (en) 2016-05-12 2022-01-19 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
MA45122A (fr) 2016-05-24 2019-04-10 Constellation Pharmaceuticals Inc Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
US10617680B2 (en) * 2017-04-18 2020-04-14 Celgene Quanticel Research, Inc. Therapeutic compounds
DK3681885T3 (da) * 2017-09-15 2024-04-15 Forma Therapeutics Inc Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer
AU2019295790B2 (en) * 2018-06-29 2023-07-13 Forma Therapeutics, Inc. Inhibiting creb binding protein (CBP)

Also Published As

Publication number Publication date
IL313466A (en) 2024-08-01
AU2023226653B2 (en) 2025-09-04
JP2021042255A (ja) 2021-03-18
KR102805503B1 (ko) 2025-05-09
SA520420909B1 (ar) 2024-11-12
IL279734B2 (en) 2024-11-01
MX2020014303A (es) 2021-03-25
RS62732B1 (sr) 2022-01-31
ES2900105T3 (es) 2022-03-15
LT3587418T (lt) 2021-11-25
HUE056885T2 (hu) 2022-03-28
US11254674B2 (en) 2022-02-22
AU2023226653A1 (en) 2023-09-21
SG11202012767UA (en) 2021-01-28
CY1124762T1 (el) 2022-07-22
AU2019295790B2 (en) 2023-07-13
US20220162207A1 (en) 2022-05-26
JP2020002135A (ja) 2020-01-09
AU2025210762A1 (en) 2025-08-21
IL279734B1 (en) 2024-07-01
IL313466B2 (en) 2025-11-01
MA50675A (fr) 2021-04-07
US20200299295A1 (en) 2020-09-24
WO2020006483A1 (en) 2020-01-02
MX2023013508A (es) 2023-12-13
CN112513038B (zh) 2023-01-10
US10870648B2 (en) 2020-12-22
JP7017801B2 (ja) 2022-02-09
JP2020128426A (ja) 2020-08-27
IL313466B1 (en) 2025-07-01
US20200002332A1 (en) 2020-01-02
DK3587418T3 (da) 2021-10-11
AU2019295790A1 (en) 2021-01-28
JP6781806B2 (ja) 2020-11-04
KR20250067962A (ko) 2025-05-15
CN112513038A (zh) 2021-03-16
ZA202210560B (en) 2025-12-17
EP3998266A1 (en) 2022-05-18
PT3587418T (pt) 2021-12-02
CN116178369A (zh) 2023-05-30
CA3105099A1 (en) 2020-01-02
IL279734A (en) 2021-03-01
KR20210025631A (ko) 2021-03-09
SMT202100636T1 (it) 2022-01-10
PL3587418T3 (pl) 2022-02-21
IL321337A (en) 2025-08-01
MA50675B1 (fr) 2021-09-30
JP2025094157A (ja) 2025-06-24
ZA202100509B (en) 2022-12-21
HRP20211698T1 (hr) 2022-02-18
US12378242B2 (en) 2025-08-05
BR112020026783A2 (pt) 2021-03-30

Similar Documents

Publication Publication Date Title
IL282179A (en) Protein tyrosine phosphatase inhibitors
IL286462A (en) Protein tyrosine phosphatase inhibitors
SI3587418T1 (sl) Zaviralci creb vezavnega proteina (cbp)
EP4241847C0 (en) ENHANCED CELL TARGETING BINDING MOLECULE
EP3630783A4 (en) PENICILLIN-BINDING PROTEIN INHIBITORS
IL281962A (en) Il-12 heterodimeric fc-fusion proteins
EP3630782A4 (en) Penicillin-binding protein inhibitors
EP3621994A4 (en) MESOTHELIN BINDING PROTEINS
EP3932338C0 (en) TURNSTILE
EP3833350A4 (en) Pyrrolopyrimidine itk inhibitors
EP3595720A4 (en) ANTIBODIES BINDING TO VISTA AT AN ACID PH
IL279355A (en) Anti-steap1 antigen-binding protein
EP3802551A4 (en) Penicillin-binding protein inhibitors
EP3902805A4 (en) CYCLINE-DEPENDENT KINASE INHIBITORS
IL280950A (en) Inhibitors of keap1-nrf2 protein-protein interaction
EP3790871C0 (en) FURIN INHIBITORS
EP3804707A4 (en) KINASE INHIBITOR
EP3661961A4 (en) ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN
EP3848293A4 (en) BINDING MACHINE
IL284317A (en) Pseudofab-based multispecific binding proteins
EP3587707C0 (en) BONDING MACHINE
EP3765265A4 (en) BINDER
EP3848292C0 (en) LINKING MACHINE
EP3848537C0 (en) LINKING MACHINE
EP3848534A4 (en) Binding machine